title: [Glucocorticoid and Bone. Collagen cross-link abnormalities in glucocorticoid induced osteoporosis].
abstract: Bone fragility is one of the side effects of glucocorticoid (GC) use, even at low doses. An increase in fracture risk due to GC administration occurs immediately after beginning treatment. A number of GC-mediated effects are responsible for bone fragility. We demonstrated that GC administration deteriorates lysyl oxidase mediated collagen crosslink formation acting as a determinant of bone material properties (Saito M, et al., Calcified Tissue Int, 88 ; 314-424, 2011) . We reviewed the mechanism of low bone material quality by GC administration.
authors.affiliation: Department of Orthopaedic Surgery, Jikei University School of Medicine, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Saito
authors.forename: Keishi
authors.initials: K
authors.lastname: Marumo
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects*; D003094:Collagen / Q000378:metabolism*; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D003094:Collagen